The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prothena Plc has an asset utilization ratio of 0.19 percent. This suggests that the company is making $0.001944 for each dollar of assets. An increasing asset utilization means that Prothena Plc is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Prothena Plc? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Prothena plc this year
Annual and quarterly reports issued by Prothena plc are formal
financial statements that are published yearly and quarterly and sent to Prothena stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Prothena Plc often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is Prothena a risky opportunity?
Let's check the volatility. Prothena is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Prothena (NASDAQ:PRTA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Prothena Plc stock makes you a part-owner of that company.
Prothena Plc Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Prothena Plc. The Prothena consensus assessment is calculated by taking the average estimates from all of the analysts covering Prothena Plc
| Strong Buy | 6 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Will Prothena Plc current rise continue?
Prothena Plc current kurtosis builds up over 19.75. Prothena Plc currently demonstrates below-verage downside deviation. It has Information Ratio of 0.07 and Jensen Alpha of 0.28. However, we do advice investors to further question Prothena Plc expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.
Our Takeaway on Prothena Plc Investment
Whereas few other entities under the biotechnology industry are still a bit expensive, Prothena Plc may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Prothena Plc.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Prothena plc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
